A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

Conditions

• Metastatic Colorectal Cancer

Eligibility Criteria

Sex

ALL

Age

14 Years - 85 Years

Healthy Volunteers

Not accepted

Interventions

• Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab — DRUG
  Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab

Study Details

A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

Key Dates

Start date

Jan 31, 2009

Status verified

Dec 2011

Study Design

Enrollment

46 participants (estimated)

Central Contacts

• Shouki Bazarbashi, M.D.
  +966-1-4423949

Related Studies

• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
  PHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  PHASE1/PHASE2 · Recruiting · Artios Pharma Ltd · Birmingham, Alabama
• A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
  PHASE1 · Recruiting · Hoffmann-La Roche · Birmingham, Alabama
• Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer
  Recruiting · University of Colorado, Denver · Aurora, Colorado